Allison Bratzel
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
29
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Overweight | $553 → $620 | $595.58 | +4.10% | 12 | Nov 1, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $28 → $42 | $28.42 | +47.78% | 3 | Oct 15, 2024 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $11 → $12 | $17.57 | -31.70% | 1 | Aug 2, 2024 | |
| ROIV Roivant Sciences | Maintains: Overweight | $20 → $22 | $11.68 | +88.36% | 2 | Jul 10, 2024 | |
| HUMA Humacyte | Maintains: Neutral | $4 | $5.39 | -25.79% | 2 | Mar 26, 2024 | |
| SLDB Solid Biosciences | Upgrades: Overweight | $8 → $20 | $5.75 | +247.83% | 4 | Mar 14, 2024 | |
| ABCL AbCellera Biologics | Assumes: Overweight | $20 | $2.73 | +632.60% | 1 | Oct 13, 2023 | |
| REPL Replimune Group | Assumes: Overweight | $44 | $11.90 | +269.75% | 1 | Apr 17, 2023 | |
| RIGL Rigel Pharmaceuticals | Assumes: Neutral | $20 | $14.20 | +40.85% | 1 | Apr 3, 2023 | |
| INCY Incyte | Maintains: Overweight | $100 | $76.13 | +31.35% | 2 | Feb 8, 2023 |
argenx SE
Nov 1, 2024
Maintains: Overweight
Price Target: $553 → $620
Current: $595.58
Upside: +4.10%
Scholar Rock Holding
Oct 15, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $28.42
Upside: +47.78%
Travere Therapeutics
Aug 2, 2024
Maintains: Neutral
Price Target: $11 → $12
Current: $17.57
Upside: -31.70%
Roivant Sciences
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $11.68
Upside: +88.36%
Humacyte
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $5.39
Upside: -25.79%
Solid Biosciences
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $5.75
Upside: +247.83%
AbCellera Biologics
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $2.73
Upside: +632.60%
Replimune Group
Apr 17, 2023
Assumes: Overweight
Price Target: $44
Current: $11.90
Upside: +269.75%
Rigel Pharmaceuticals
Apr 3, 2023
Assumes: Neutral
Price Target: $20
Current: $14.20
Upside: +40.85%
Incyte
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $76.13
Upside: +31.35%